Urticaria

This trial asks whether adding a Mediterranean diet or a low-histamine diet to standard care can reduce disease activity and improve quality of life in teens aged 12-18 with chronic spontaneous urticaria (CSU), a condition causing persistent hives. Participants are randomly assig…

This program provides access to an experimental oral medication called deucrictibant for people with hereditary angioedema (HAE) who have no satisfactory alternative treatments for acute attacks. Eligible participants, aged 12 to 75, take the capsule as needed to manage swelling …

This early-stage trial tests a single oral dose of HRS-3095, a new drug for chronic spontaneous urticaria (chronic hives), in 36 healthy adults. The main goal is to check safety and how the drug moves through the body. Results will guide future studies in patients with hives.

This study follows 470 adults with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will track how well it controls symptoms and any side effects over two years in real-world clinics. The goal is to see if remibrutinib works as well out…

This phase 3 study tests an intravenous C1 esterase inhibitor (C1-INH) in people with hereditary angioedema (HAE) to treat acute attacks and prevent attacks before medical procedures. About 124 participants, aged 2 and older, will receive either the drug or a placebo. The main go…

This program provides access to an investigational drug called donidalorsen for people with hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling in various body parts. The drug is given as a monthly or every-other-month injection under the skin. I…

This study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…

This study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main go…

This study tests an investigational drug called barzolvolimab in 240 adults who get hives from cold temperatures or from scratching their skin, and whose symptoms are not controlled by standard allergy pills. Participants receive either the drug or a placebo injection, and doctor…

This program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children …

This study tests an experimental drug called BBT001 in adults with chronic spontaneous urticaria, a condition causing frequent hives without a clear trigger. Participants receive multiple doses of BBT001 or a placebo to see if it is safe and helps control symptoms. The trial focu…

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…

This study compares two standard treatments for bleeding internal hemorrhoids: hemorrhoidal artery embolization (HAE) and rubber band ligation (RBL). HAE uses a catheter to block blood flow to the hemorrhoid with tiny particles or coils, while RBL uses rubber bands to cut off cir…

This study looks at how well an injection called Immunoglobulin-Histamine complex (IHC, brand name Histoglob) works for people with chronic urticaria, or long-term hives. Researchers will track 600 patients in India to see if the treatment reduces hives and the need for other all…

This Phase 3 trial tests an oral drug called deucrictibant in adults with acquired angioedema due to C1 inhibitor deficiency, a rare condition causing sudden, painful swelling attacks. The study has three parts: one to see if a daily extended-release tablet can prevent attacks, a…

This phase 3 trial is testing an experimental drug called ADX-324 in 90 adults with hereditary angioedema (HAE) types 1 or 2. HAE causes sudden, painful swelling in the body. ADX-324 uses a technology called siRNA to lower levels of a protein involved in triggering these attacks.…

This study is for people with hereditary angioedema (HAE) who have already completed a previous trial of the drug ADX-324. ADX-324 is an RNA-based medicine designed to lower a protein involved in swelling attacks. The goal is to see if long-term use is safe and can reduce the num…

This study follows 200 people with hereditary angioedema (HAE) who are starting garadacimab in routine medical care. Researchers will track how well the drug prevents swelling attacks, its safety, and its impact on quality of life over 48 months. The goal is to see if results fro…

This study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world ef…

This Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…

This study tests an experimental pill called ICP-332 in 344 adults with moderate to severe chronic spontaneous urticaria (hives) that antihistamines can't control. Participants will take the drug or a placebo for 12 or 24 weeks. The main goal is to see if the drug reduces itching…

This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and…

This study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…

This Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…

This study tests whether a single injection of Berinert, a protein that reduces inflammation, into a donor kidney just before transplant can improve kidney function in the first year. Researchers will compare this to a placebo in 180 high-risk patients receiving deceased-donor ki…

This study is observing 225 adults with severe allergic asthma or chronic hives who are already doing well on the original omalizumab drug. Their doctors have decided to switch them to a biosimilar version called Omlyclo. The main goal is to see if they stay well-controlled for 1…

This study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal i…

This program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access t…

This study looks at whether people with chronic spontaneous urticaria (long-term hives) who are well-controlled on omalizumab every 4 weeks can switch to every 6 weeks without losing control. Forty adults will be randomly assigned to continue standard dosing or extend their injec…

This study offers children aged 2 to 11 with hereditary angioedema (HAE) continued access to garadacimab, a lab-made antibody that helps prevent sudden, painful swelling attacks. Participants must have completed a prior study and shown good response with few or no attacks. The go…

This study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part.…

This study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…

This study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…

This study tests whether a mobile app that provides psychological tools can improve quality of life for people with eczema, psoriasis, or chronic hives. Participants use the app over 32 weeks to learn coping strategies and wellness tips. The goal is to see if this digital approac…

This study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…

This study compares the standard dose of cetirizine (10 mg daily) to a higher dose (40 mg daily) for treating acute hives in adults. Researchers want to see if the higher dose relieves symptoms faster and reduces the need for steroid rescue medication. Participants take the assig…

This study tests a procedure called hemorrhoidal artery embolization (HAE) for people with internal hemorrhoids who have not had success with other treatments or cannot have surgery. The procedure blocks certain arteries to reduce blood flow to the hemorrhoid tissue, aiming to im…

This early-stage study tests a single dose of an experimental drug called GTX-B001 in healthy people and those with chronic inducible urticaria—a condition where cold or scratching causes painful hives. The main goal is to check safety and how the body handles the drug. About 72 …

This study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…

This study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who took Takhzyro (lanadelumab) to prevent attacks. Researchers want to see if the drug reduces HAE activity and improves quality of life after 6 to 12 months. No new treatments…

This study is building a large database and biobank from 2200 people with chronic inflammatory diseases like lupus, multiple sclerosis, severe asthma, and psoriasis. Researchers will collect blood samples and track disease activity over time using standard medical scores. The goa…

This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…

This study aims to understand how a type of white blood cell called eosinophils contributes to DRESS syndrome, a severe and potentially life-threatening drug allergy. Researchers will compare blood and skin samples from 80 adults with DRESS, other drug rashes, and healthy volunte…

This study uses smartphone surveys to track the real-life burden of hereditary angioedema (HAE) in 30 adults. Participants answer quick questions about their symptoms, mood, and daily activities every other day for 8 weeks. The goal is to capture day-to-day changes that standard …

This study aims to find the genetic causes behind certain allergic and immune system disorders. Researchers will collect blood, saliva, and tissue samples from up to 10,000 people of all ages, along with some family members. No treatments are given; the goal is simply to learn mo…

This study aims to find biological markers (biomarkers) that can help diagnose and monitor chronic induced urticaria (CIndU), a condition where specific triggers like cold or pressure cause itchy hives or swelling. Researchers will compare 40 participants—including people with CI…

This study is creating a large database to collect information on people with rare diseases like amyloidosis, sarcoidosis, and Gaucher disease. Researchers will track patients' health over time, including their symptoms, treatments, and outcomes. The goal is to improve diagnosis …

This study looks at different forms of IgE (a protein involved in allergic reactions) in healthy volunteers and people with conditions like severe allergies, chronic hives, mastocytosis, and immune deficiencies. Researchers aim to understand how these IgE variations relate to hea…